Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The experimental vaccines use the same technology as the highly effective Moderna COVID-19 shot.
With $600,000 in amfAR HIV grants, research teams explore CAR-T cells, bFAbs and CRISPR/Cas9 gene editing to eradicate the reservoir.
Two experimental vaccine approaches, using mRNA protein delivery and germline targeting, are in the early stages of development.
HIV treatment usually requires daily pills, but longer-acting regimens are gaining ground.
That’s the hope of research funded by a new Campbell Foundation grant.
Products based on broadly neutralizing antibodies could be used in HIV treatment and prevention.
The new coronavirus crisis has upended the clinical trials process around the world.
Researchers used a harmless virus to deliver a gene for a broadly neutralizing HIV antibody to cells, which produced the antibody over time.
Temporarily off antiretrovirals, participants received antibody injections, which boosted CD4 and CD8 cell responses to HIV.
For the first time, researchers are assessing a pairing of a long-acting antiretroviral and a long-acting antibody.
An $80,000 grant from The Campbell Foundation will help scientist Natalia Freund continue her HIV vaccine studies.
A series of antibody infusions suppressed HIV for up to four months without prompting the virus to develop resistance.
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against HIV.
Today, with better understanding of the complex task at hand, cure researchers are investigating multiple avenues and taking the long view.
Researchers were also able to make the first-ever estimate of the level of antibodies needed for protection against the virus.
An antibody treatment plus an immune-stimulating agent delayed viral rebound in primates infected with HIV-like virus.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.